Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacytidine + CAOLD
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous Or Subcutaneous (for Azacytidine), Intravenous (for Caold Components, Likely)
01
Overview
Azacytidine (azacitidine) is a chemotherapy drug and epigenetic modulator that works by inhibiting DNA methyltransferase, leading to hypomethylation of DNA and reactivation of tumor suppressor genes. The "CAOLD" regimen is a combination chemotherapy protocol used in the treatment of relapsed/refractory peripheral T-cell lymphomas, but its specific components are not detailed in available public sources. The combination of azacytidine with the CAOLD regimen is being investigated for safety and efficacy in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and other peripheral T-cell lymphomas[1][2][3]. This therapy aims to improve response rates, progression-free survival, overall survival, and tolerability compared to standard treatments.
- Other names
- Azacitidine plus CAOLD Regimen
02
Targets
DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on azacytidine + CAOLD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacytidine + CAOLD.